Bruker Corporation (NASDAQ:BRKR) Receives $50.62 Average Target Price from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned a consensus rating of “Hold” from the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $52.8571.

A number of analysts have recently weighed in on the company. Cowen restated a “hold” rating on shares of Bruker in a research note on Tuesday, November 4th. Barclays upped their target price on shares of Bruker from $45.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday. Bank of America raised their price target on shares of Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday. UBS Group upped their price objective on Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, Rothschild & Co Redburn assumed coverage on Bruker in a research note on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price for the company.

Bruker Stock Performance

Bruker stock opened at $45.67 on Friday. The firm has a market capitalization of $6.94 billion, a P/E ratio of -285.44, a P/E/G ratio of 6.64 and a beta of 1.17. The stock has a fifty day moving average price of $41.86 and a two-hundred day moving average price of $38.39. Bruker has a 52-week low of $28.53 and a 52-week high of $64.64. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, analysts anticipate that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insider Transactions at Bruker

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director directly owned 35,212 shares in the company, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its position in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. Huntington National Bank increased its holdings in Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the last quarter. Spire Wealth Management bought a new stake in Bruker in the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd lifted its stake in Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the period. Finally, Allworth Financial LP boosted its holdings in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.